| Jan 2022 | Erich Piovan and collegues at University of Padua collaborated with Sciomics to study specific biomarkers in FFPE tissue samples of DLBCL patients by custom antibody microarrays.
| September 2024 | Four identified serum proteins may advance diagnostic and therapeutic approaches by complementing traditional diagnostic laboratory variables. Sciomics contributed to this study by a scioCD serum analysis targeting different CD surface markers, cytokines and chemokines.
| April 2023 | New Article: In a protein biomarker development project initiated by Sciomics, we have identified protein biomarker panels predicting development of a severe Covid.19 disease.
| Mai 2023 | New Article: Galadima et al. used the scioCD assay to analyse canine blood samples in the context of mammary neoplasia. The proteins CD20, CD45RA and CD99 were found at altered levels. The findings were validated by Western Blotting and are suggested as novel serum biomarkers.
| Feb 2021 | Scientists at Heidelberg University Hospital used our scioCD platform to profile CD8+SLAMF7+ cell cultures:
"High throughput screening of 351 different cytokines and immune proteins in the supernatants of the T cells cultures revealed strong upregulation of IL-6, IL-8, both vital survival factors for myeloma cells, and CXCL5, a chemokine that could enhance the frequency of CD4 Treg, in the cultures containing CD8+SLAMF7+ cells. IL-2 and IL-5 were upregulated in the control cultures without CD8+SLAMF7+ T cells, highlighting a more activated state in the control group and suggestion IL-6 and IL-8 as potential effector cytokines for the suppressive CD8+SLAMF7+ T cells."
Awwad, M. H. S. et al. ‘Selective elimination of immunosuppressive T cells in patients with multiple myeloma’, Leukemia 35 2602-2615 (2021)
Tara Sigdel, PhD
Associate Professor, Department of Surgery, University of California San Francisco
"We collaborated with Sciomics GmbH in Germany to analyze proteomics data from blood samples of kidney transplant recipients and liver perfusates during normothermic machine perfusion. Throughout the process, Sciomics provided exceptional support, ensuring timely data delivery and valuable assistance with data analysis. Their expertise and commitment have been instrumental in advancing our research, and we are currently using their data in multiple manuscript submissions. I highly recommend Sciomics for their reliable service and expertise in proteomics."
Product: scioDiscover
Dr. Matthew Wright
Chief Scientific Officer, Kinarus Therapeutics AG, Basel, Switzerland
"We are a small biotech company without our own wet labs. Sciomics recommended a UK CRO that performed cell culture experiments for our studies. Sciomics seamlessly coordinated the transfer of the biologic materials to their facility and performed the scioCD panel to characterize cell surface markers and cytokines in cell lines treated with our small molecule drug candidates. The Sciomics data were instrumental in supporting our IP protection strategy. Their advice was very helpful and they worked with us to extract the most out of the data. We are very satisfied and highly recommend the Sciomics platform and the team."
Product: scioCD
